- Fireside chat will address KRAS inhibition and the promise of onvansertib as a new therapeutic option in colorectal cancer

- Phase 1b: 7 (33%) of evaluable patients achieved an objective response, with a complete response (CR/CRi) in 5 (31%) patients treated at the four highest onvansertib dose levels

-- Initiation of Expanded Access Program follows FDA granting Fast Track Designation of onvansertib for second-line treatment of patients with KRAS-mutation mCRC

- Positive data presented at ASCO follows announcement of Fast Track Designation granted by the FDA for onvansertib in second-line treatment of patients with KRAS-mutated mCRC

- The U.S. Food and Drug Administration reviewed the Company's request for Fast Track designation and concluded that investigation of onvansertib, in combination with FOLFIRI/bevacizumab, for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer meets the criteria for a Fast Track development program